Videos

Thomas Herzog, MD, clinical director, University of Cincinnati Cancer Institute, discusses the types of patients who benefit from neoadjuvant therapies. Patients who cannot undergo aggressive cytoreduction, patients with comorbidities and older patients would be ideal candidates to receive the therapy, he adds.

Arun Singh, MD, assistant professor, Division of Hematology-Oncology, University of California, Los Angeles (UCLA), discusses a phase Ib/II trial of immunotherapy for patients with advanced sarcoma.

Sant P. Chawla, MD, director, Sarcoma Oncology Center, discusses the potential for trabectedin as treatment of mesenchymal chondrosarcoma.

George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses the trial the led to the approval of trabectedin (Yondelis) for advanced leiomyosarcoma or liposarcoma.

Robin L. Jones, BSc, MB, MRCP, MD, Consultant Oncologist, Royal Marsden Hospital, London, England, discusses results and takeaways from a phase III trial presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.

Dr. Jonathan Trent discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.

Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, talks about use of PD-1 inhibitors in ovarian cancer and the lack of evidence pointing toward their functionality.

Dr. Judy C. Boughey talks about a study examining all patients at Mayo Clinic that underwent a nipple-sparing mastectomy for breast cancer and comparing those with positive lymph nodes to those with negative lymph nodes.

Gregory J. Riely, MD, PhD, vice chair of the Clinical Trials Office in the Department of Medicine, Memorial Sloan Kettering Cancer Center, talks about non-small cell lung cancer (NSCLC) MET exon 14 mutations and their response to drugs like cabozantinib and crizotinib.

Jedd D. Wolchok, MD, PhD, chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center in New York City, talks about the phase III CheckMate 067 trial.

Jason J. Luke, MD, FACP, assistant professor of medicine, The University of Chicago, discusses the international MSLT-II trial, which looks at the possibility of less surgery for melanoma patients in the future.

Pamela Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, talks about the findings of the phase II study of everolimus plus bevacizumab in pNETs, as well as bevacizumab in progressive pNETS.

Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, what community oncologists can take away from the phase III placebo-controlled TELESTAR trial, which evaluated telotristat etiprate in patients with inadequately controlled carcinoid syndrome.

Christiane Kuhl, MD, Professor of Radiology and Vice Chairman of the Radiological department, Director of the Division of Oncologic Imaging and Interventional Therapy, Bonn University, talks about the over diagnosis of breast cancer through mammography screenings.

Mayer Fishman, MD, PhD, Medical Oncologist, Moffitt Cancer Center, talks about the phase Ib/II study of an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin in advanced or metastatic chemo-refractory urothelial cancer (UC).

Hans-Christian Kolberg, MD, doctor of Medicine, Marien Hospital Bottrop in Bottrop, Germany, discusses neoadjuvant chemotherapy with docetaxel, carboplatin, and weekly trastuzumab for patients with HER2-positive early breast cancer.

Frank A. Sinicrope, MD, talks about sporadic mismatch repair deficient colonic cancer tumors compared to familial related to germ line mutations in the setting of Lynch syndrome.

Dirk Arnold, MD, PhD, Professor and Head Dept. Hematology and Medical Oncology at Tumor Biology Center in Freiburg, Germany, talks about sirflox and its phase III trials on whether or not it can properly add local ablative treatment to diffuse metastasization of the liver.

Unresectable Hepatocellular carcinoma with Amit Singal, MD and Richard Finn, MD

Steven D. Gore, MD, director of Hematologic Malignancies at Yale Cancer Center, talks about the risk of constantly testing azanucleoside combinations without significant results. Gore says that testing azanucleoside combinations that are not well planned may cause the medical community to overlook an effective combination due to fatigue of constant testing.

Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, talks about the vague understanding medical professional currently have of HER-2 breast cancer and its resistance to certain therapies.

Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses upcoming trials for the HER2-antibody margetuximab.

Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1, which has the potential to play a major role in the treatment of breast cancer.

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, talks about the importance of women knowing which genetic tests they�ve previously had done for breast cancer.